Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered as Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults With Mild Asthma

NCT06563102 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06563102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered as Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults With Mild Asthma
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 11, 2024
Completion date
February 24, 2026
Enrollment
101 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

mild asthma